Novotech

UK, India sign deal to support R&D, innovation projects

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Firefly Bio Acquisition Strengthens J&J Cancer Pipeline

Johnson & Johnson (J&J) has entered into a definitive...

Sanofi and Owkin Partner to Co-Develop Agentic AI Tools for Drug Discovery

Sanofi has entered into a multi-year agreement with France-based...

Pfizer and Innovent Finalize $10.5 Billion Global Oncology Agreement

The Pfizer Innovent Cancer Deal has been finalized, establishing...
- Advertisement -

The Technology Strategy Board (TSB) in the UK and the Indian government’s Department of Science and Technology have signed ‘Programme of Co-operation’ deal to support joint, collaborative research and development (R&D) and innovation projects in key areas, including energy and healthcare.

Under the agreement, the TSB and the Indian Global Innovation and Technology Alliance (GITA), sponsored by the Indian government, support the UK and Indian businesses and academics over a three year period.

The TSB will contribute ยฃ5m to the project, which is the first international partnership by the UK public body outside Europe.

TSB chief executive Iain Gray said, “These programmes not only help build and strengthen links between countries but will help build the international partnerships between businesses so vital in today’s global economy.”

The Programme of Co-operation is expected to expand further over a period of time, for the mutual benefit of businesses from both countries.

World Pharma Today brings together the global pharmaceutical industry โ€” from R&D leaders and regulatory affairs professionals to manufacturers and distribution executives โ€” through trusted editorial, market intelligence, and digital engagement.

Our 2026 Media Pack offers integrated solutions to reach your audience:

  • Magazine & Digital Editions Showcase your brand within premium pharmaceutical industry coverage read by executives and decision - makers worldwide.
  • Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global pharmaceutical and life sciences value chain.
  • Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.

Latest stories

Related stories

Firefly Bio Acquisition Strengthens J&J Cancer Pipeline

Johnson & Johnson (J&J) has entered into a definitive...

Sanofi and Owkin Partner to Co-Develop Agentic AI Tools for Drug Discovery

Sanofi has entered into a multi-year agreement with France-based...

Pfizer and Innovent Finalize $10.5 Billion Global Oncology Agreement

The Pfizer Innovent Cancer Deal has been finalized, establishing...

Transforming the Future of Pharmaceutical Innovation

The pharmaceutical industry stands at the edge of a...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป